Drug General Information (ID: DDI0LKP867)
Drug Name			Abiraterone		Drug Info		Radium Ra 223 dichloride		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Diagnostic Radiopharmaceuticals

Mechanism of Abiraterone-Radium Ra 223 dichloride Interaction (Severity Level: Major)
Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Abiraterone				Radium Ra 223 dichloride
Mechanism		Abiraterone				Increase the risk of death and fractures in combination with abiraterone
Key Mechanism Factor 1
		Factor Name		Adverse reactions
		Factor Description		An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
Mechanism Description		Increased risk of adverse reactions by the combination of Abiraterone and Radium Ra 223 dichloride

Recommended Action
Management		Until more information is available, use of radium Ra 223 dichloride with abiraterone and prednisone/prednisolone should be considered contraindicated. US authorities are prohibiting the start of new treatments with this combination and suspending use in patients currently receiving these drugs in combination in favor of other therapeutic alternatives. Some authorities recommend that subsequent treatment with radium Ra 223 dichloride should not be initiated for at least 5 days after the last administration of abiraterone in combination with prednisone/prednisolone (AU, UK, EU). In addition, continued monitoring for fractures should be considered for patients previously treated with the combination. Preliminary evidence suggests that use of bone health agents such as bisphosphonates or denosumab may diminish the risk of fractures.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Bayer HealthCare Pharmaceuticals, Inc "Important Drug Warning: Xofigo."